2024
Solano, G., Cunningham, S., Edge, R. J., Duran, G., Sanchez, A., Villalta, M., . . . Ainsworth, S. (2024). African polyvalent antivenom can maintain pharmacological stability and ability to neutralise murine venom lethality for decades post-expiry: evidence for increasing antivenom shelf life to aid in alleviating chronic shortages.. BMJ global health, 9(3), e014813. doi:10.1136/bmjgh-2023-014813DOI: 10.1136/bmjgh-2023-014813
2023
Menzies, S. K., Arinto-Garcia, R., Amorim, F. G., Cardoso, I. A., Abada, C., Crasset, T., . . . Schaffitzel, C. (2023). ADDovenom: Thermostable Protein-Based ADDomer Nanoparticles as New Therapeutics for Snakebite Envenoming.. Toxins, 15(12), 673. doi:10.3390/toxins15120673DOI: 10.3390/toxins15120673
OC 78.5 Systemic Snakebite Envenoming Causes Histone-Induced Thrombocytopaenia (Journal article)
Schofield, J., Abrams, S., Alhamdi, Y., Ainsworth, S., Evans, C., Albulescu, L., . . . Toh, C. (2023). OC 78.5 Systemic Snakebite Envenoming Causes Histone-Induced Thrombocytopaenia. Research and Practice in Thrombosis and Haemostasis, 7, 100487. doi:10.1016/j.rpth.2023.100487DOI: 10.1016/j.rpth.2023.100487
2022
Menzies, S. K., Litschka-Koen, T., Edge, R. J., Alsolaiss, J., Crittenden, E., Hall, S. R., . . . Harrison, R. A. (2022). Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing. PLOS NEGLECTED TROPICAL DISEASES, 16(9). doi:10.1371/journal.pntd.0010496DOI: 10.1371/journal.pntd.0010496
Menzies, S. K., Dawson, C. A., Crittenden, E., Edge, R. J., Hall, S. R., Alsolaiss, J., . . . Ainsworth, S. (2022). Virus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition. SCIENTIFIC REPORTS, 12(1). doi:10.1038/s41598-022-13376-xDOI: 10.1038/s41598-022-13376-x
Alomran, N., Blundell, P., Alsolaiss, J., Crittenden, E., Ainsworth, S., Dawson, C. A., . . . Casewell, N. R. (2022). Exploring the Utility of Recombinant Snake Venom Serine Protease Toxins as Immunogens for Generating Experimental Snakebite Antivenoms. TOXINS, 14(7). doi:10.3390/toxins14070443DOI: 10.3390/toxins14070443
Exploring the utility of recombinantly expressed snake venom serine protease toxins as immunogens for generating experimental snakebite antivenoms (Preprint)
DOI: 10.1101/2022.05.07.491032
Menzies, S. K., Clare, R. H., Xie, C., Westhorpe, A., Hall, S. R., Edge, R. J., . . . Casewell, N. R. (2022). In vitro and in vivo preclinical venom inhibition assays identify metalloproteinase inhibiting drugs as potential future treatments for snakebite envenoming by Dispholidus typus. Toxicon: X, 14, 100118. doi:10.1016/j.toxcx.2022.100118DOI: 10.1016/j.toxcx.2022.100118
<i>In vitro</i> and <i>in vivo</i> venom-inhibition assays identify metalloproteinase-inhibiting drugs as potential treatments for snakebite envenoming by <i>Dispholidus typus</i> (Journal article)
Menzies, S. K., Clare, R. H., Xie, C., Westhorpe, A., Hall, S. R., Edge, R. J., . . . Casewell, N. R. (2022). <i>In vitro</i> and <i>in vivo</i> venom-inhibition assays identify metalloproteinase-inhibiting drugs as potential treatments for snakebite envenoming by <i>Dispholidus typus</i>. doi:10.1101/2022.01.07.475313DOI: 10.1101/2022.01.07.475313
